Literature DB >> 33396906

MiR-146a Regulates Migration and Invasion by Targeting NRP2 in Circulating-Tumor Cell Mimicking Suspension Cells.

Yeojin Do1, Jin Gu Cho1, Ji Young Park1, Sumin Oh1, Doyeon Park1, Kyung Hyun Yoo1,2, Myeong-Sok Lee1,2, Byung Su Kwon3, Jongmin Kim1,2, Young Yang2.   

Abstract

Cancer metastasis is the primary cause of cancer-related death and metastatic cancer has circulating-tumor cells (CTCs), which circulate in the bloodstream before invading other organs. Thus, understanding the precise role of CTCs may provide new insights into the metastasis process and reduce cancer mortality. However, the molecular characteristics of CTCs are not well understood due to a lack of number of CTCs. Therefore, suspension cells were generated from MDA-MB-468 cells to mimic CTCs, and we investigate the microRNA (miRNA)-dependent molecular networks and their role in suspension cells. Here, we present an integrated analysis of mRNA and miRNA sequencing data for suspension cell lines, through comparison with adherent cells. Among the differentially regulated miRNA-mRNAs axes, we focus on the miR-146a-Neuropilin2 (NRP2) axis, which is known to influence tumor aggressiveness. We show that miR-146a directly regulates NRP2 expression and inhibits Semaphorin3C (SEMA3C) signaling. Functional studies reveal that miR-146a represses SEMA3C-induced invasion and proliferation by targeting NRP2. Finally, high-NRP2 is shown to be associated with poor outcomes in breast cancer patients. This study identifies the key role of the miR-146a-NRP2 signaling axis that is critical for the regulation of migration and invasion in CTC-mimicking cells.

Entities:  

Keywords:  MicroRNA; circulating-tumor cell; metastasis; neuropilin2 (NRP2); semaphorin3C (SEMA3C); suspension cell

Mesh:

Substances:

Year:  2020        PMID: 33396906      PMCID: PMC7824086          DOI: 10.3390/genes12010045

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  46 in total

1.  Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5.

Authors:  Chengshuai Si; Qiao Yu; Yufeng Yao
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447

2.  Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

Authors:  Bhavna Murali; Qihao Ren; Xianmin Luo; Douglas V Faget; Chun Wang; Radia Marie Johnson; Tina Gruosso; Kevin C Flanagan; Yujie Fu; Kathleen Leahy; Elise Alspach; Xinming Su; Michael H Ross; Barry Burnette; Katherine N Weilbaecher; Morag Park; Gabriel Mbalaviele; Joseph B Monahan; Sheila A Stewart
Journal:  Cancer Res       Date:  2018-08-09       Impact factor: 12.701

3.  Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells.

Authors:  M A Matrone; R A Whipple; K Thompson; E H Cho; M I Vitolo; E M Balzer; J R Yoon; O B Ioffe; K C Tuttle; M Tan; S S Martin
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

4.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Authors:  Douglas R Hurst; Mick D Edmonds; Gary K Scott; Christopher C Benz; Kedar S Vaidya; Danny R Welch
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

5.  MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer.

Authors:  Qin Liu; Wei Wang; Xiongfa Yang; Dongxiao Zhao; Fangqiong Li; Hai Wang
Journal:  Oncol Rep       Date:  2016-05-06       Impact factor: 3.906

6.  Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma.

Authors:  Xiaogang Dong; Wenjia Guo; Shizhen Zhang; Tianchun Wu; Zhongquan Sun; Sheng Yan; Shusen Zheng
Journal:  Onco Targets Ther       Date:  2017-07-31       Impact factor: 4.147

Review 7.  Circulating and disseminated tumor cells: harbingers or initiators of metastasis?

Authors:  Arko Dasgupta; Andrea R Lim; Cyrus M Ghajar
Journal:  Mol Oncol       Date:  2017-01       Impact factor: 6.603

8.  miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells.

Authors:  Jing-Pei Long; Li-Feng Dong; Fang-Fang Chen; Yang-Fan Fan
Journal:  Oncol Lett       Date:  2018-11-28       Impact factor: 2.967

9.  Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Authors:  Jeffrey B Smerage; William E Barlow; Gabriel N Hortobagyi; Eric P Winer; Brian Leyland-Jones; Gordan Srkalovic; Sheela Tejwani; Anne F Schott; Mark A O'Rourke; Danika L Lew; Gerald V Doyle; Julie R Gralow; Robert B Livingston; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 50.717

10.  CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.

Authors:  Sheng Huang; Yayun Chi; Yi Qin; Ziliang Wang; Bingqiu Xiu; Yonghui Su; Rong Guo; Liang Guo; Hefen Sun; Chujia Zeng; Shuling Zhou; Xin Hu; Sheng Liu; Zhimin Shao; Zhaohui Wu; Wei Jin; Jiong Wu
Journal:  Theranostics       Date:  2018-04-03       Impact factor: 11.556

View more
  3 in total

Review 1.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

Review 2.  Neuropilin (NRPs) Related Pathological Conditions and Their Modulators.

Authors:  Matic Broz; Anja Kolarič; Marko Jukič; Urban Bren
Journal:  Int J Mol Sci       Date:  2022-07-29       Impact factor: 6.208

3.  Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour.

Authors:  Xiao-Mao Tian; Bin Xiang; Li-Ming Jin; Tao Mi; Jin-Kui Wang; Chenghao Zhanghuang; Zhao-Xia Zhang; Mei-Ling Chen; Qin-Lin Shi; Feng Liu; Tao Lin; Guang-Hui Wei
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.